What is drug compounding, and are compounded drugs FDA-approved?

Compounding is the preparation of a tailored medicine. Section 503A covers patient-specific compounding by a licensed pharmacist in a state-licensed pharmacy, or a licensed physician, based on a valid prescription. Section 503B covers FDA-registered outsourcing facilities that can compound larger batches under current good manufacturing practice. Both are exempt from the section 505 approval requirement, but compounded drugs are still not FDA-approved, meaning the FDA does not review their safety, effectiveness, or quality before they are marketed.

What is the difference between section 503A and section 503B?

Section 503A is patient-specific compounding by a state-licensed pharmacy or physician against a valid prescription; these compounders are overseen mainly by state boards of pharmacy and are not required to follow current good manufacturing practice. Section 503B outsourcing facilities register with the FDA, can compound larger batches including office stock, and must follow current good manufacturing practice under FDA oversight. The two-track split was created by the 2013 Drug Quality and Security Act.

As of June 2026, is BPC-157 FDA-approved or legal to compound?

No. BPC-157 is not FDA-approved. The FDA placed BPC-157 and other peptides into Category 2 of its interim 503A bulk-substances review in 2023. In 2026 the FDA removed twelve peptides from Category 2 and scheduled a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026. Crucially, removal from Category 2 does not make these substances eligible for compounding. As of June 2026 the status is unsettled and pending that review.

What does 'not FDA-approved' actually mean?

It means the FDA has not reviewed that substance or product for safety, effectiveness, or quality before it is marketed. It is a statement about what review has not happened, not a verdict that a product is safe or unsafe. Compounded drugs in particular are not FDA-approved.

Module 2 of 5

The US framework: FDA and compounding

The US medicines system rests on one law: the Federal Food, Drug, and Cosmetic Act. This module walks through how a drug gets approved, the narrow compounding carve-outs, and the unsettled 2023 to 2026 peptide story, in plain language.

Read this first. This page is education only and is not legal advice. It describes US federal law only; state law varies and can be stricter. Regulatory positions in this area change often, so treat everything here as a dated snapshot that is current as of June 2026. For your own situation, consult a licensed attorney. Nothing here is permission or instruction to buy, sell, import, or use any peptide.

The starting rule: a new drug needs FDA approval

The center of the US system is section 505 of the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. 355). In plain terms: no one may put a "new drug" into interstate commerce unless the FDA has approved an application for it. This is a rule about marketing a product, not a rule about what happens in a private exam room.

Why this matters for peptides. Most peptides sold online have never been through this process, so they are unapproved new drugs. That single fact sits underneath almost every other legal question in this course.

The compounding carve-out: 503A and 503B

There is a narrow exception to the approval rule. Compounding is the preparation of a tailored medicine, and the law carves out two tracks that are exempt from the section 505 approval requirement. The two-track split was created by the 2013 Drug Quality and Security Act. Read the next line carefully: even compounded drugs are not FDA-approved.

The point people miss. "Compounded at a pharmacy" is not the same as "FDA-approved." The FDA does not review a compounded drug's safety, effectiveness, or quality before it is marketed. The compounding tracks are exemptions from approval, not substitutes for it.

The bulk-substance lists: Category 1 and Category 2

Compounders sometimes start from a raw bulk drug substance rather than an approved product. For 503A compounding, the FDA's interim policy sorts nominated bulk substances into categories. This is the list where the entire peptide story plays out.

Snapshot, not stone. These lists are interim and the FDA updates how it handles nominated substances over time. The exact contents can move, so the lists are best read as a dated snapshot, current as of June 2026.

The peptide timeline (2023 to 2026)

This is the fastest-moving part of the whole topic, so read it precisely and note the date. The status below is a snapshot as of June 2026. None of it means any of these peptides is "approved" or "freely compoundable."

Do not misread this. As of June 2026, the legal status of BPC-157 and the other listed peptides is unsettled and pending PCAC review. Removal from Category 2 is not FDA approval and is not a ruling that they are eligible to compound. Sources also differ on the exact counts and dates, which is another reason to re-check the live FDA list before relying on any of it.

What "not FDA-approved" actually means

This phrase gets used loosely, so here is the precise meaning. "Not FDA-approved" means the FDA has not reviewed the substance or product for safety, effectiveness, or quality before it is marketed. It describes a review that has not happened, rather than a verdict that something is safe or unsafe.

Plain-language version. "FDA-approved" is a specific milestone: the agency looked at the evidence and signed off before marketing. "Not FDA-approved" simply means that milestone has not been reached, which is the situation for compounded drugs and for most peptides sold for human use.

Common questions about the US framework

Short, sourced answers to the questions people ask most about FDA approval and compounding. These are educational summaries of US federal law as of June 2026, not legal advice.

Does a peptide need FDA approval to be sold as a drug?

Yes. Under section 505 (21 U.S.C. 355), no one may introduce a new drug into interstate commerce without an effective FDA-approved application, and approval requires proof of both safety and effectiveness.

Are compounded drugs FDA-approved?

No. Sections 503A and 503B exempt compounding from the section 505 approval rule, but compounded drugs are still not FDA-approved; the FDA does not review their safety, effectiveness, or quality before they are marketed.

What is the difference between 503A and 503B?

503A is patient-specific compounding by a state-licensed pharmacy or physician against a valid prescription, overseen mainly by state boards. 503B outsourcing facilities register with the FDA, compound batches, and must follow current good manufacturing practice.

As of June 2026, is BPC-157 approved or legal to compound?

No. It is not FDA-approved. It was placed in Category 2 in 2023; in 2026 the FDA removed twelve peptides from Category 2 and scheduled a PCAC meeting for July 23-24, 2026. Removal from Category 2 does not make it eligible to compound. The status is unsettled and pending.

What does "not FDA-approved" mean?

It means the FDA has not reviewed the product for safety, effectiveness, or quality before marketing. It is a statement about review that did not happen, not a verdict that the product is safe or unsafe.

U.S. Code, 21 U.S.C. § 355 (FD&C Act § 505), "New drugs," 2022 ed. (GPO / govinfo). govinfo.gov
U.S. Code, 21 U.S.C. § 353a (FD&C Act § 503A), "Pharmacy compounding," 2022 ed. (GPO / govinfo). govinfo.gov
U.S. Code, 21 U.S.C. § 353b (FD&C Act § 503B), "Outsourcing facilities," 2022 ed. (GPO / govinfo). govinfo.gov
FDA, "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A," final interim guidance, Federal Register Jan. 7, 2025 (Doc. 2024-31546). federalregister.gov
FDA, "Understanding the Risks of Compounded Drugs" (Human Drug Compounding). fda.gov
Frier Levitt, "FDA to Remove 12 Popular Peptides from the Category 2 'Do Not Compound' List" (2026). frierlevitt.com
BioSpace, "FDA mulls compounding for peptides previously flagged over safety risks" (2026). biospace.com

Knowledge check

Test what you learned in this module.

Practice exercises

Reinforce your understanding with interactive exercises.

Next module

Drug vs supplement vs research chemical